Trial record 1 of 3 for:
RXC004
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04907539 |
|
Recruitment Status :
Completed
First Posted : May 28, 2021
Last Update Posted : May 3, 2024
|
Sponsor:
Redx Pharma Plc
Information provided by (Responsible Party):
Redx Pharma Plc
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | April 2, 2024 |
| Actual Study Completion Date : | April 2, 2024 |